ALS medical marijuana condition guide

Amyotrophic Lateral Sclerosis (ALS)


Sahar Mustafa profile photoby Sahar Mustafa
Last updated:
Medically reviewed by: Dr. Hannah Russo, MD, MPH
Fact Checked
Share article:
Share on TwitterShare on FacebookShare on LinkedIn

What is ALS?

Amyotrophic lateral sclerosis, aka Lou Gehrig’s Disease, is a rare neurological disorder that attacks nerve cells that control voluntary muscle movement. Voluntary muscles are the ones we choose to move and control things like walking, writing, chewing, and talking. Unfortunately, there is no cure for ALS, and symptoms typically progress and worsen over time.

ALS is a motor neuron disease caused by the gradual deterioration and death of motor neurons. Motor neurons are nerve cells that connect the brain to the spinal cord and muscles throughout the body. As motor neurons degenerate, they stop sending messages to the muscles, and the muscles gradually weaken, twitch, and waste away. Eventually, the brain loses its ability to initiate and control voluntary movements.

Early symptoms of ALS usually include muscle weakness or stiffness. Gradually all voluntary muscles are affected, and patients eventually lose their strength and the ability to speak, eat, move, and breathe. Most people with ALS die from respiratory failure within three to five years of the symptoms’ first appearance. Approximately ten percent of people with ALS survive for ten or more years.

Who is Lou Gehrig?

amyotrophic lateral sclerosis was identified as a disease in 1869 by French neurologist Jean-Martin Charcot. The disease became widely known in June 1941, when it ended the career of one of American baseball’s best and most beloved players, Lou Gehrig. Even now, ALS is commonly referred to as Lou Gehrig’s disease.

What are the symptoms?

The onset of amyotrophic lateral sclerosis (ALS) can be subtle, but these symptoms gradually develop into more obvious symptoms, including:

  • Muscle cramps in the arm, leg, shoulder, or tongue
  • Tight and stiff muscles
  • Muscle weakness affecting arms, legs, neck, or diaphragm
  • Slurred speech
  • Difficulty chewing or swallowing

What causes ALS?

The cause of amyotrophic lateral sclerosis is unknown, and scientists do not yet know why the disease affects some people and not others. However, evidence suggests that genetic and environmental factors play a role in motor neuron degeneration and ALS development.

Risk factors for ALS include:

  • Age. Although ALS can strike at any age, symptoms commonly develop between 55 and 75.
  • Gender. Men are more likely than women to develop ALS. However, as people age, the difference between men and women disappears.
  • Race and ethnicity. Caucasians and non-Hispanics are most likely to develop the disease.

How is ALS diagnosed?

There isn’t an official test that provides a diagnosis of amyotrophic lateral sclerosis. It is usually diagnosed based on a detailed history of the symptoms observed by a physician, a review of the individual’s complete medical record, and a series of tests to rule out other diseases and track for signs of worsening symptoms.

Medical Cannabis as ALS Treatment

Therapeutic options for amyotrophic lateral sclerosis, the most common adult-onset motor neuron disorder, remain limited. Emerging evidence from clinical studies and transgenic mice models of ALS suggests that cannabinoids, the bioactive ingredients of Cannabis sativa, might have some therapeutic benefit for this condition. However, Delta 9-THC, the predominant cannabinoid in marijuana, induces mind-altering effects and is partially addictive, compromising its clinical effectiveness.

Scientists tested whether CBN, a non-psychotropic cannabinoid, influences disease progression and survival in the SOD1 rat model of ALS. CBN was delivered via subcutaneously implanted osmotic mini-pumps over 12 weeks. Researchers found that this treatment significantly delayed disease onset by more than two weeks while not affecting survival rates. This study is still in its early stages. Further research and human studies are necessary to determine whether non-psychotropic cannabinoids might help alleviate amyotrophic lateral sclerosis symptoms compared to other drugs.

Last Updated: June 14, 2024

Sahar Mustafa profile photo

Meet the author

Sahar Mustafa

Hi, I'm Sahar. At LeafyDoc, I write about medical marijuana cards, renewals, state requirements, costs, and the online evaluation process. I like writing clear, useful content that makes everything feel less complicated for readers. Cannabis regulations can change from one state to another, so I focus on helping readers understand what applies to them and what they can expect next.

Get Approved for Your Medical Marijuana Card in Minutes!

Start My Evaluation
Smiling medical marijuana patient ready to start their card evaluation

Why Patients Trust Our Guidance

Medical cannabis is surrounded by outdated information, and patients are the ones left guessing. That is why every article on Leafy DOC is reviewed by licensed medical professionals with direct experience caring for cannabis patients. Their expertise keeps our guidance medically sound, easy to follow, and genuinely useful at every stage of your cannabis care. Read every page knowing a qualified doctor has already vetted it.

Reviewed by

Dr. Hannah Russo, MD, MPH

Internal Medicine Physician, Master of Public Health

Dr. Hannah Russo is an internal medicine doctor and public health advocate with extensive experience in telemedicine and cannabis education. Her work bridges clinical practice and digital health, ensuring that patients receive safe, informed, and convenient care. She is passionate about expanding access to natural, evidence-based therapies for chronic conditions.

Professional headshot of Dr. Hannah Russo wearing a white lab coat

Written by:

Sahar Mustafa

Last reviewed:

Having a hard time to decide?

Chat with your favorite AI chat assistant or book a consultation with our healthcare team to discover how Leafy DOC can support your medical cannabis journey!